Ticker
    GILD

    Price
    63.59
    Stock movement down
    -0.03 (-0.05%)
    Company name
    Gilead Sciences Inc
    Exchange
    (NASDAQ
    ,
    Currency
    USD
    )
    Sector
    Healthcare >
    Drug Manufacturers-General
    Market cap
    79.76B
    Ent value
    118.63B
    Price/Sales
    2.90
    Price/Book
    -
    Div yield
    4.59%
    Div growth
    9.07%
    Growth years
    6
    FCF payout
    26.35%
    Trailing P/E
    17.67
    Forward P/E
    10.01
    PEG
    12.62
    EPS growth
    -10.50%
    1 year return
    -10.95%
    3 year return
    0.31%
    5 year return
    -2.92%
    10 year return
    8.45%
    Last updated: 2022-08-25

    DIVIDENDS

    Dividend yield - 5y

    Dividend yield data
    Dividend per share2.92
    Dividend yield4.59%
    Payout frequencyQuarterly
    Maximum yield5.06%
    Average yield3.83%
    Minimum yield2.43%
    Discount to avg yield16.50%
    Upside potential19.75%
    Yield as % of max yield90.77%

    Yield distribution (inverse percentile) - 5y

    Yield distribution data
    Dividend yield4.59%
    Current yield distribution11.35%
    Yield at 100% (Min)2.43%
    Yield at 90%2.92%
    Yield at 80%3.17%
    Yield at 50% (Median)3.93%
    Yield at 20%4.35%
    Yield at 10%4.65%
    Yield at 0% (Max)5.06%

    Dividend per share

    Dividend per share data
    Years of growth6 years
    CCC statusDividend Challenger
    Dividend per share2.92
    Payout frequencyQuarterly
    Ex-div date14 Sep 2022
    EPS (TTM)3.58
    EPS (1y forward)6.35
    EPS growth (5y)-10.50%
    EPS growth (5y forward)1.40%

    Dividend growth

    Please create a free account or log in to access this chart
    Dividend growth data
    GILDS&P500
    DGR MR2.82%15.44%
    DGR TTM3.20%7.80%
    DGR 3 years7.60%3.88%
    DGR 5 years9.07%4.73%
    DGR 10 years-8.30%
    DGR 15 years-5.82%
    Time since last change announced237 days
    EPS growth (5y)-10.50%
    EPS growth (5y forward)1.40%

    Payout ratio

    Please create a free account or log in to access this chart
    Payout ratio data
    EPS coverageFCF coverage
    TTM59.53%26.35%
    Average--
    Forward45.98%-

    VALUATION

    Valuation Ratios

    Valuation Ratios data
    Trailing P/E17.67
    Price to OCF7.51
    Price to FCF7.82
    Price to EBITDA9.55
    EV to EBITDA14.20

    Valuation (Sales/Book Value)

    Valuation (Sales/Book Value) data
    Price to Sales2.90
    Price to Book-
    EV to Sales4.32

    FINANCIALS

    Per share

    Per share data
    Current share count1.25B
    EPS (TTM)3.58
    FCF per share (TTM)8.08

    Income statement

    Income statement data
    Revenue (TTM)27.47B
    Gross profit (TTM)20.81B
    Operating income (TTM)7.22B
    Net income (TTM)4.51B
    EPS (TTM)3.58
    EPS (1y forward)6.35

    Margins

    Margins data
    Gross margin (TTM)75.74%
    Operating margin (TTM)26.30%
    Profit margin (TTM)16.43%

    Balance Sheet

    Please create a free account or log in to access this chart
    Balance Sheet data
    Cash4.30B
    Net receivables3.79B
    Total current assets12.63B
    Goodwill8.31B
    Intangible assets30.33B
    Property, plant and equipment0.00
    Total assets63.08B
    Accounts payable583.00M
    Short/Current long term debt26.21B
    Total current liabilities8.56B
    Total liabilities43.16B
    Shareholder's equity0.00
    Net tangible assets-18.72B

    Cash flow

    Please create a free account or log in to access this chart
    Cash flow data
    Operating cash flow (TTM)10.61B
    Capital expenditures (TTM)414.00M
    Free cash flow (TTM)10.20B
    Dividends paid (TTM)2.69B

    Financial returns

    Please create a free account or log in to access this chart
    Financial returns data
    Return on Equity-
    Return on Assets7.16%
    Return on Invested Capital-
    Cash Return on Invested Capital-

    STOCK INFORMATION

    Stock chart

    Stock price data
    Open63.85
    Daily high63.93
    Daily low63.18
    Daily Volume3.69M
    All-time high122.21
    1y analyst estimate69.40
    Beta0.39
    EPS (TTM)3.58
    Dividend per share2.92
    Ex-div date14 Sep 2022
    Next earnings date26 Oct 2022

    Downside potential

    Downside potential data
    GILDS&P500
    Current price drop from All-time high-47.97%-12.18%
    Highest price drop-70.83%-56.47%
    Date of highest drop7 Jun 19949 Mar 2009
    Avg drop from high-24.87%-11.38%
    Avg time to new high24 days12 days
    Max time to new high1808 days1805 days
    COMPANY DETAILS
    GILD (Gilead Sciences Inc) company logo
    Marketcap
    79.76B
    Marketcap category
    Large-cap
    Description
    Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
    Employees
    14400
    Website
    https://www.gilead.com
    Investor relations
    http://investors.gilead.com
    SEC filings
    GILD SEC filings
    CEO
    Daniel O'Day
    Country
    USA
    City
    Foster City
    Stock type
    Common stock
    CCC status
    Dividend Challenger
    Dividend Frequency
    Quarterly
    EVENTS AND PRESENTATIONS
    EventsPresentations
    UNDERSTAND THE BUSINESS
    COMPANY NEWS
    All newsPress releases
    Institutional owners may take dramatic actions as Gilead Sciences, Inc.'s (NASDAQ:GILD) recent 4.2% drop adds to one-year losses
    A look at the shareholders of Gilead Sciences, Inc. ( NASDAQ:GILD ) can tell us which group is most powerful. We can...
    September 24, 2022
    4 Questions With Dr. Javier Cortes: The Importance of Scientific Exchange To Advance Breast Cancer
    NORTHAMPTON, MA / ACCESSWIRE / September 23, 2022 / Gilead Sciences For Dr. Javier Cortes, being a breast cancer researcher isn't just a profession - it's a calling. As the head of the International B...
    September 23, 2022
    Got $1,000? 2 Stocks That Could Be Bargain Buys For 2022 and Beyond
    Let's look at two biotech stocks that look attractive at current levels: AbbVie (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD). AbbVie is one of the largest pharmaceutical companies around. Like ot...
    September 23, 2022
    Biotech Stock Roundup: GILD, BMY's Regulatory News, BLUE's Therapy Approval & More
    Regulatory and pipeline updates from BMY and GILD are the key highlights from the biotech sector during the past week.
    September 22, 2022
    Gilead Joins First-of-its-Kind Public-Private Initiative to Improve Management of Viral Hepatitis in Vietnam and the Philippines
    FOSTER CITY, Calif., September 22, 2022--Gilead Sciences, Inc. today announced a new public-private initiative with the Partnership for Health Advancement in Vietnam (HAIVN), a collaboration between B...
    September 22, 2022
    Gilead Sciences (GILD) Stock Moves -1.67%: What You Should Know
    Gilead Sciences (GILD) closed at $63.50 in the latest trading session, marking a -1.67% move from the prior day.
    September 21, 2022
    Quant Billionaire Jim Simons Loves These 10 Defensive Stocks
    In this article, we discuss 10 defensive stocks that quant billionaire Jim Simons loves. If you want to read about some more stocks in the Simons portfolio, go directly to Quant Billionaire Jim Simons...
    September 21, 2022
    Gilead Sciences Completes Acquisition of MiroBio
    FOSTER CITY, Calif., September 20, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire MiroBio, a privately held U.K.-based bio...
    September 20, 2022
    Gilead Sciences, Inc.'s (NASDAQ:GILD) latest 3.2% decline adds to one-year losses, institutional investors may consider drastic measures
    If you want to know who really controls Gilead Sciences, Inc. ( NASDAQ:GILD ), then you'll have to look at the makeup...
    September 20, 2022
    Gilead (GILD) Drugs Get Positive CHMP Opinion for Label Expansion
    Gilead's (GILD) COVID-19 treatment Veklury and CAR T-cell therapy Yescarta get positive CHMP recommendation for additional indications.
    September 19, 2022
    Next page
    Social
    Menu
    Home
    Portfolio Management
    Company Screener
    Green Investment
    About us
    Blog (HU)
    Contact support
    Language EN | HU | NO
    Disclaimer
    iO Charts assumes no responsibility or liability for any errors or omissions in the content of this site. The information contained in this site is provided on an “as is” basis with no guarantees of completeness, accuracy, usefulness or timeliness. Please also note, that any action you take upon the information provided on this website is strictly at your own risk. This website is intended to be used and must be used for informational purposes only and you should take independent financial advice from a professional and independently research and verify everything you see on the site.
    © 2021 iO Charts All Rights Reserved